These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
255 related items for PubMed ID: 7999842
1. Long-term effect of oral calcitriol single weekly pulse in CAPD and in HD. Romanini D, Gazo A, Bellazzi R, de Vincenzi A, Nai M, Santagostino M. Adv Perit Dial; 1994; 10():267-9. PubMed ID: 7999842 [Abstract] [Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L. Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [Abstract] [Full Text] [Related]
3. Pulse oral calcitriol to treat hyperparathyroidism in 43 CAPD patients. Juergensen P, Santacroce S, Mooraki A, Cooper K, Finkelstein FO, Kliger AS. Adv Perit Dial; 1994 Nov; 10():259-60. PubMed ID: 7999840 [Abstract] [Full Text] [Related]
4. Effects of calcitriol pulse therapy per os in CAPD patients. Scanziani R, Dozio B, Bonforte G, Surian M. Adv Perit Dial; 1994 Nov; 10():270-4. PubMed ID: 7999844 [Abstract] [Full Text] [Related]
5. Effect of CAPD and hemodialysis on parathyroid function. Malberti F, Corradi B, Imbasciati E. Adv Perit Dial; 1996 Nov; 12():239-44. PubMed ID: 8865912 [Abstract] [Full Text] [Related]
7. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM. Am J Nephrol; 2008 Nov; 28(1):97-106. PubMed ID: 17914251 [Abstract] [Full Text] [Related]
8. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients. Bajo MA, Selgas R, Possante C, Aguilera A, Sánchez C, Diaz C, de Alvaro F, Martinez ME. Adv Perit Dial; 1997 Nov; 13():239-43. PubMed ID: 9360690 [Abstract] [Full Text] [Related]
9. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study. Gu Y, Ding F, Chen N, Mei CL, Qian JQ, Wang XY, Shi W, Hou FF, Li XW, Wang M, Chen YP. Ren Fail; 2005 Nov; 27(2):205-12. PubMed ID: 15807187 [Abstract] [Full Text] [Related]
10. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients. Wadhwa NK, Suh H, Howell N, Cabralda T, Sokunbi D, Solomon M. Adv Perit Dial; 1993 Nov; 9():260-3. PubMed ID: 8105939 [Abstract] [Full Text] [Related]
11. High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory secondary hyperparathyroidism. Malberti F, Scanziani R, Corradi B, Dozio B, Bonforte G, Imbasciati E, Surian M. Nephrol Dial Transplant; 1994 Nov; 9(12):1813-5. PubMed ID: 7708273 [Abstract] [Full Text] [Related]
12. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Panichi V, Andreini B, De Pietro S, Migliori M, Taccola D, Giovannini L, Ferdeghini M, Palla R. Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556 [Abstract] [Full Text] [Related]
13. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. Khajehdehi P, Taheri S. J Ren Nutr; 2003 Apr; 13(2):78-83. PubMed ID: 12671829 [Abstract] [Full Text] [Related]
14. Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients. Lomonte C, Martino R, Selvaggiolo M, Bona RM, Cazzato F, Milano R, Chiarulli G, Basile C. J Nephrol; 2003 Apr; 16(5):716-20. PubMed ID: 14733419 [Abstract] [Full Text] [Related]
15. [Oral calcitriol pulse therapy in treatment of secondary hyperparathyroidism in patients with long term hemodialysis]. Szołkiewicz M, Zdrojewski Z, Sulima-Gillow A, Rutkowski B. Przegl Lek; 1996 Apr; 53(5):427-30. PubMed ID: 8754407 [Abstract] [Full Text] [Related]
16. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients. Brossard JH, Roy L, Lepage R, Gascon-Barré M, D'Amour P. Miner Electrolyte Metab; 1997 Apr; 23(1):25-32. PubMed ID: 9058366 [Abstract] [Full Text] [Related]
17. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients. Peng SJ, Yang CS, Ferng SH, Chen LY. Miner Electrolyte Metab; 1997 Apr; 23(1):13-8. PubMed ID: 9058364 [Abstract] [Full Text] [Related]
18. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD. Macia M, Coronel F, Navarro JF, Gallego E, Herrero JA, Méndez ML, Chahin J, García J. Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490 [Abstract] [Full Text] [Related]
19. A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis. Banalagay E, Bernardini J, Holley J, Chen T, Piraino B. Adv Perit Dial; 1993 Sep; 9():280-3. PubMed ID: 8105943 [Abstract] [Full Text] [Related]
20. Secondary hyperparathyroidism in CAPD patients: its suppressibility with high doses of calcitriol. Felipe C, Miranda B, Selgas R, Martinez ME, Miguel JL, Moreno F, Caparros G, Torre A, Sicilia LS. Adv Perit Dial; 1990 Sep; 6():238-41. PubMed ID: 1982816 [Abstract] [Full Text] [Related] Page: [Next] [New Search]